Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protocatechualdehyde is a naturally occurring phenolic aldehyde found in various plants such as barley, green cavendish bananas, grapevine leaves, and the root of Salvia miltiorrhiza. It is a small molecule with notable antiproliferative and pro-apoptotic properties against human breast cancer and colorectal cancer cells by reducing the expression of pro-oncogenes β-catenin and cyclin D1[1][2][3]. Mechanistically, it inhibits cell growth and promotes apoptosis through HDAC2-mediated cyclin D1 suppression in colorectal cancer cells and activates proteasomal degradation pathways in breast cancer cells[3]. Protocatechualdehyde also exhibits antioxidant, anti-inflammatory, antibacterial activities; it has been studied for its protective effects on nerve cells (e.g., cerebral ischemia injury), cardiovascular diseases (including myocardial infarction), liver protection/regeneration, antifibrosis activity in tissues/organs (including liver), wound healing promotion, as well as potential benefits for diabetic complications via modulation of targets such as AKT1, MAPK3/ERK1 and HDAC3[4][5][6][7]. It is considered experimental with no established pharmaceutical approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on protocatechualdehyde.